Drug combo helps High-Risk kidney patients avoid full kidney removal
NCT ID NCT06138496
First seen Jan 05, 2026 · Last updated Apr 28, 2026 · Updated 17 times
Summary
This study tested whether giving a combination of two drugs (cadonilimab and lenvatinib) before surgery could shrink kidney tumors enough to allow a partial, kidney-sparing operation instead of full removal. It included 39 adults with clear cell kidney cancer whose tumors were large or in tricky locations. The goal was to see if the drugs made surgery safer and more successful.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Other (Non U.s.), 0755, China
Conditions
Explore the condition pages connected to this study.